IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lessened by Atria Investments Inc

Atria Investments Inc reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,430 shares of the company's stock after selling 709 shares during the quarter. Atria Investments Inc's holdings in IDEXX Laboratories were worth $1,005,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of IDXX. Flossbach Von Storch SE lifted its position in shares of IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $113,104,000. Vontobel Holding Ltd. increased its holdings in shares of IDEXX Laboratories by 90.1% in the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after acquiring an additional 198,404 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $62,391,000. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of analyst reports. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Finally, Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Remove Ads

IDEXX Laboratories Stock Down 3.3 %

IDXX stock opened at $412.40 on Thursday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm's 50-day moving average is $438.09 and its two-hundred day moving average is $448.02. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $550.24. The company has a market capitalization of $33.54 billion, a price-to-earnings ratio of 38.65, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.18% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.